The DOI matches its Crossref record; 45 of the 45 references it cites were found in a registry or an index.
Cognitive Enhancers as Adjuncts to Psychotherapy: Use of D-Cycloserine in Phobic Individuals to Facilitate Extinctionof Fear
Abstract
BACKGROUND: Traditional pharmacological approaches to treating psychiatric disorders focus on correcting presumed biochemical abnormalities. However, some disorders, particularly the anxiety-related disorders exemplified by specific phobia, have an emotional learning component to them that can be facilitated with psychotherapy. OBJECTIVE: To determine whether D-cycloserine (DCS), a partial agonist at the N-methyl-d-aspartate receptor that has previously been shown to improve extinction of fear in rodents, will also improve extinction of fear in human phobic patients undergoing behavioral exposure therapy. DESIGN: Randomized, double-blind, placebo-controlled trial examining DCS vs placebo treatment in combination with a precisely controlled exposure paradigm. SETTING: Participants were recruited from the general community to a research clinic. PARTICIPANTS: Twenty-eight subjects with acrophobia diagnosed by the Structured Clinical Interview for DSM-IV were enrolled. INTERVENTIONS: After we obtained pretreatment measures of fear, subjects were treated with 2 sessions of behavioral exposure therapy using virtual reality exposure to heights within a virtual glass elevator. Single doses of placebo or DCS were taken prior to each of the 2 sessions of virtual reality exposure therapy. Subjects, therapists, and assessors were blind to the treatment condition. Subjects returned at 1 week and 3 months posttreatment for measures to determine the presence and severity of acrophobia symptoms. MAIN OUTCOME MEASURES: Included were measures of acrophobia within the virtual environment, measures of acrophobia in the real world, and general measures of overall improvement. An objective measure of fear, electrodermal skin fluctuation, was also included during the virtual exposure to heights. Symptoms were assessed by self-report and by independent assessors at approximately 1 week and 3 months posttreatment. RESULTS: Exposure therapy combined with DCS resulted in significantly larger reductions of acrophobia symptoms on all main outcome measures. Subjects receiving DCS had significantly more improvement compared with subjects receiving placebo within the virtual environment (1 week after treatment, P</=.001; 3 months later, P</=.05). Subjects receiving DCS also showed significantly greater decreases in posttreatment skin conductance fluctuations during the virtual exposure (P</=.05). Additionally, subjects receiving DCS had significantly greater improvement compared with subjects receiving placebo on general measures of real-world acrophobia symptoms (acrophobia avoidance [P</=.02], acrophobia anxiety [P</=.01], attitudes toward heights [P</=.04], clinical global improvement [P</=.01], and number of self-exposures to real-world heights [P</=.01]); the improvement was evident early in treatment and was maintained at 3 months. CONCLUSION: These pilot data provide initial support for the use of acute dosing of DCS as an adjunct to exposure-based psychotherapy to accelerate the associative learning processes that contribute to correcting psychopathology.
Overview
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
Claims other papers make about this one
Each is checked against this paper’s own text: does it say what the citing paper says it does?
In the citing paper
“DCS is an agonist of the N-methyl-D-aspartate (NMDA) glutamate receptor, and it has been shown to increase the efficacy of exposure therapies for a number of anxiety disorders (Hofmann, Sawyer, and Asnaani, 2012; Ressler, Rothbaum, Tannenbaum, Anderson, et al. 2004).”
From Advancing the treatment of anxiety disorders in transition‐age youth: a review of the therapeutic effects of unconscious exposure. (2025) · cites this paper as Ressler, Rothbaum, Tannenbaum, Anderson, et al. 2004
In the citing paper
“Participants who received the drug (oral administration two to four hours before each session) showed greater improvements than those who received a placebo.”
From Mediators and Mechanisms of Change in Psychotherapy Research (2007) · cites this paper as Ressler et al. 2004
In the citing paper
“The effects were evident one week and three months after treatment.”
From Mediators and Mechanisms of Change in Psychotherapy Research (2007) · cites this paper as Ressler et al. 2004
In the citing paper
“Recently, DCS combined with imaginal or virtual reality exposure (VRE) therapy has been shown to reduce length of treatment for some anxiety disorders, including acrophobia (Ressler et al, 2004), social phobia (Guastella et al, 2008; Hofmann et al, 2006), and panic disorder (Otto et al, 2010), which, like PTSD, include learned avoidance and cued emotional distress as salient symptoms.”
From D-cycloserine augmentation of exposure therapy for post-traumatic stress disorder: a pilot randomized clinical trial (2014) · cites this paper as Ressler et al, 2004
In the citing paper
“The choice of dosing regimen for our studies was based on the Ressler et al (2004) study, which showed that there was no difference in efficacy between the 50 and 500 mg dose of DCS on enhancing exposure therapy outcomes.”
From D-cycloserine augmentation of exposure therapy for post-traumatic stress disorder: a pilot randomized clinical trial (2014) · cites this paper as Ressler et al (2004)
In the citing paper
“We chose weekly dosing, administered 90 min before exposure sessions, as this regimen has been effective in multiple animal and human fear extinction studies (Ledgerwood et al, 2003; Ressler et al, 2004; Walker et al, 2002)”
From D-cycloserine augmentation of exposure therapy for post-traumatic stress disorder: a pilot randomized clinical trial (2014) · cites this paper as Ressler et al, 2004
In the citing paper
“These pilot data add to the literature showing that DCS-enhanced exposure therapy is effective for the treatment of anxiety disorders (Hofmann et al, 2006; Ressler et al, 2004).”
From D-cycloserine augmentation of exposure therapy for post-traumatic stress disorder: a pilot randomized clinical trial (2014) · cites this paper as Ressler et al, 2004
In the citing paper
“Our data, in conjunction with that of Ressler et al (2004), Hofmann et al (2006), and Otto et al (2010), form a compelling pattern of evidence supporting the hypothesis that DCS may facilitate extinction learning.”
From D-cycloserine augmentation of exposure therapy for post-traumatic stress disorder: a pilot randomized clinical trial (2014) · cites this paper as Ressler et al, 2004
In the citing paper
“Shortly thereafter, several groups reported that DCS administration before or after exposure therapy, a form of treatment based on the principles of fear extinction learning, was effective in alleviating the symptoms of acrophobia (67), panic disorder (68), social anxiety disorder (69, 70), and obsessive–compulsive disorder (71–73).”
From Conditioned fear associated phenotypes as robust, translational indices of trauma-, stressor-, and anxiety-related behaviors (2014) · cites this paper as [67]
In the citing paper
“The rationale for selecting 50 mg as the dose was that this dose showed efficacy in previous work examining exposure enhancement with pre-session administration of DCS (10, 11).”
From D-cycloserine enhancement of fear extinction is specific to successful exposure sessions: evidence from the treatment of height phobia (2013) · cites this paper as [10]
In the citing paper
“In humans, DCS administration can likewise facilitate the loss of fear resulting from exposure that causes incomplete fear loss in controls (acrophobia: Ressler, Rothbaum, Tannenbaum, Anderson, Graap, Zimand, Hodges, & Davis, 2004; social phobia: Guastella, Richardson, Lovibond, Rapee, Gaston, Mitchell, & Dadds, 2008; Hofmann, Meuret, Smits, Simon, Pollack, Eisenmenger, Shiekh, & Otto, 2006;”
From D-cycloserine facilitates context-specific fear extinction learning (2008) · cites this paper as Ressler, Rothbaum, Tannenbaum, Anderson, Graap, Zimand, Hodges, & Davis, 2004
In the citing paper
“Indeed, in clinical studies, Ressler et al (2004) and Hofmann et al (2006) have recently reported that DCS facilitates fear extinction in patients with anxiety disorders.”
From Effects of Single Prolonged Stress and D-Cycloserine on Contextual Fear Extinction and Hippocampal NMDA Receptor Expression in a Rat Model of PTSD (2008) · cites this paper as Ressler et al, 2004
In the citing paper
“This, considered collectively with findings from animal studies, leads to the postulation that DCS administration without extinction training cannot facilitate fear extinction.”
From Effects of Single Prolonged Stress and D-Cycloserine on Contextual Fear Extinction and Hippocampal NMDA Receptor Expression in a Rat Model of PTSD (2008) · cites this paper as Ressler et al, 2004
In the citing paper
“Heresco-Levy et al (2002) used daily chronic dosing without exposure therapy, while Hofmann et al (2006) and Ressler et al (2004) used acute dosing with exposure therapy.”
From Effects of Single Prolonged Stress and D-Cycloserine on Contextual Fear Extinction and Hippocampal NMDA Receptor Expression in a Rat Model of PTSD (2008) · cites this paper as Ressler et al (2004)
Citations
Cites
An inventory for measuring depression
BECK, A. T. (1961) · Archives of General Psychiatry · doi:10.1001/archpsyc.1961.01710120031004 · Cited by 38,032
The Structured Clinical Interview for DSM-III-R (SCID): I: History, Rationale, and Description
Spitzer, R. L. (1992) · Archives of General Psychiatry · doi:10.1001/archpsyc.1992.01820080032005 · Cited by 4,336
Manual for the state-trait anxiety inventory (form Y) : "self-evaluation questionnaire"
Spielberger, C. D., Gorsuch, R. L., & Lushene, R. E. (1970) · Consulting Psychologists Press eBooks · Cited by 2,352
Genetic enhancement of learning and memory in mice
Tang, Y., Shimizu, E., Dubé, G., Rampon, C., Kerchner, G. A., Zhuo, M., Liu, G., & Tsien, J. Z. (1999) · Nature · doi:10.1038/43432 · Cited by 1,878
Context, ambiguity, and unlearning: sources of relapse after behavioral extinction
Bouton, M. E. (2002) · Biological Psychiatry · doi:10.1016/s0006-3223(02)01546-9 · Cited by 1,662
Barlow, D. H., Gorman, J. M., Shear, M. K., & Woods, S. W. (2000) · JAMA · doi:10.1001/jama.283.19.2529 · Cited by 953
Behavioral and Neural Analysis of Extinction
Myers, K. M., & Davis, M. (2002) · Neuron · doi:10.1016/s0896-6273(02)01064-4 · Cited by 918
Self-citationMiserendino, M. J. D., Sananes, C. B., Melia, K. R., & Davis, M. (1990) · Nature · doi:10.1038/345716a0 · Cited by 824
Self-citationWalker, D. L., Ressler, K. J., Lu, K.-T., & Davis, M. (2002) · The Journal of Neuroscience · doi:10.1523/jneurosci.22-06-02343.2002 · Cited by 815
Self-citationEffectiveness of computer-generated (virtual reality) graded exposure in the treatment of acrophobia
(1995) · American Journal of Psychiatry · doi:10.1176/ajp.152.4.626 · Cited by 694
Self-citation
Flagged first, then by citations
Cited by
Sorted by citations
Items 201–300 of 1,000
Converging Cognitive Enhancements
Sandberg, A., & Bostrom, N. (2006) · Annals of the New York Academy of Sciences · doi:10.1196/annals.1382.015 · Cited by 125
Powers, M. B., Smits, J. A. J., Otto, M. W., Sanders, C., & Emmelkamp, P. M. G. (2009) · Journal of Anxiety Disorders · doi:10.1016/j.janxdis.2009.01.001 · Cited by 122
Augmentation Treatment of Psychotherapy for Anxiety Disorders with D‐Cycloserine
Hofmann, S. G., Pollack, M. H., & Otto, M. W. (2006) · CNS Drug Reviews · doi:10.1111/j.1527-3458.2006.00208.x · Cited by 123
Evidence-Based Psychological Treatments: An Update and a Way Forward
Barlow, D. H., Bullis, J. R., Comer, J. S., & Ametaj, A. A. (2013) · Annual Review of Clinical Psychology · doi:10.1146/annurev-clinpsy-050212-185629 · Cited by 120
Estrogen and Extinction of Fear Memories:Implications for Posttraumatic Stress Disorder Treatment
Glover, E. M., Jovanović, T., & Norrholm, S. D. (2015) · Biological Psychiatry · doi:10.1016/j.biopsych.2015.02.007 · Cited by 131
Animal models in translational studies of PTSD
Daskalakis, N. P., Yehuda, R., & Diamond, D. M. (2013) · Psychoneuroendocrinology · doi:10.1016/j.psyneuen.2013.06.006 · Cited by 127
D-cycloserine facilitates context-specific fear extinction learning
Bouton, M. E., Vurbic, D., & Woods, A. M. (2008) · Neurobiology of Learning and Memory · doi:10.1016/j.nlm.2008.07.003 · Cited by 118
“In humans, DCS administration can likewise facilitate the loss of fear resulting from exposure that causes incomplete fear loss in controls (acrophobia: Ressler et al., 2004; social phobia: Guastella et al., 2008; Hofmann et al., 2006; obsessive–compulsive disorder: Kushner et al., 2007).”
BackgroundNMDA receptors and fear extinction: implications for cognitive behavioral therapy
Davis, M. (2011) · Dialogues in Clinical Neuroscience · doi:10.31887/dcns.2011.13.4/mdavis · Cited by 120
Self-citationBrain sites involved in fear memory reconsolidation and extinction of rodents
Baldi, E., & Bucherelli, C. (2015) · Neuroscience & Biobehavioral Reviews · doi:10.1016/j.neubiorev.2015.04.003 · Cited by 123
Contributions of the d-serine pathway to schizophrenia
Labrie, V., Wong, A. H. C., & Roder, J. (2011) · Neuropharmacology · doi:10.1016/j.neuropharm.2011.01.030 · Cited by 121
Lopresto, D., Schipper, P., & Homberg, J. R. (2015) · Neuroscience & Biobehavioral Reviews · doi:10.1016/j.neubiorev.2015.10.009 · Cited by 125
Virtual reality exposure therapy for combat‐related posttraumatic stress disorder
ROTHBAUM, B. O., Rizzo, A., & Difede, J. (2010) · Annals of the New York Academy of Sciences · doi:10.1111/j.1749-6632.2010.05691.x · Cited by 117
Self-citationVirtual Reality and Interactive Digital Game Technology: New Tools to Address Obesity and Diabetes
Rizzo, A., Lange, B. S., Suma, E. A., & Bolas, M. T. (2011) · Journal of Diabetes Science and Technology · doi:10.1177/193229681100500209 · Cited by 117
Labrie, V., & Roder, J. (2009) · Neuroscience & Biobehavioral Reviews · doi:10.1016/j.neubiorev.2009.08.002 · Cited by 118
Is it time to revisit the role of psychedelic drugs in enhancing human creativity?
Sessa, B. (2008) · Journal of Psychopharmacology · doi:10.1177/0269881108091597 · Cited by 115
Reichel, C. M., Moussawi, K., Do, P. H., Kalivas, P. W., & See, R. E. (2011) · Journal of Pharmacology and Experimental Therapeutics · doi:10.1124/jpet.111.179317 · Cited by 116
Smits, J. A. J., Rosenfield, D., Otto, M. W., Marques, L., Davis, M. L., Meuret, A. E., Simon, N. M., Pollack, M. H., & Hofmann, S. G. (2013) · Journal of Psychiatric Research · doi:10.1016/j.jpsychires.2013.06.020 · Cited by 114
“…across these studies, with several evidencing strong augmentative effects of DCS (Guastella et al., 2008; Hofmann et al., 2006; Otto et al., 2010; Ressler et al., 2004), and several showing either relatively weak effects (Kushner et al., 2007; Wilhelm et al., 2008), no effects (Guastella et al.,…”
BackgroundSelf-citationSleep enhances exposure therapy
Kleim, B., Wilhelm, F. H., Temp, L., Margraf, J., Wiederhold, B. K., & Rasch, B. (2014) · Psychological Medicine · doi:10.1017/s0033291713001748 · Cited by 113
Tronel, S., & Alberini, C. M. (2007) · Biological Psychiatry · doi:10.1016/j.biopsych.2006.09.009 · Cited by 110
Myers, K. M., & Carlezon, W. A. (2010) · Neuroscience & Biobehavioral Reviews · doi:10.1016/j.neubiorev.2010.01.011 · Cited by 113
Virtual Reality Exposure Therapy
ROTHBAUM, B. O. (2010) · The Corsini Encyclopedia of Psychology · doi:10.1002/9780470479216.corpsy1024 · Cited by 110
Self-citationDoes D-cycloserine enhance exposure therapy for anxiety disorders in humans? A meta-analysis
Rodrigues, H., Figueira, I., Lopes, A., Gonçalves, R., Mendlowicz, M. V., Coutinho, E. S. F., & Ventura, P. (2014) · PLoS ONE · doi:10.1371/journal.pone.0093519 · Cited by 109
Carhart-Harris, R. L., Wall, M. B., Erritzoe, D., Kaelen, M., Ferguson, B., De Meer, I., Tanner, M., Bloomfield, M., Williams, T. M., Bolstridge, M., et al. (2014) · The International Journal of Neuropsychopharmacology · doi:10.1017/s1461145713001405 · Cited by 108
How to erase memory traces of pain and fear
Sandkühler, J., & Lee, J. L. C. (2013) · Trends in Neurosciences · doi:10.1016/j.tins.2013.03.004 · Cited by 108
Storch, E. A., Wilhelm, S., Sprich, S. E., Henin, A., Micco, J. A., Small, B. J., Mcguire, J. F., Mutch, P. J., Lewin, A. B., Murphy, T. K., et al. (2016) · JAMA Psychiatry · doi:10.1001/jamapsychiatry.2016.1128 · Cited by 111
Structural Determinants of d-Cycloserine Efficacy at the NR1/NR2C NMDA Receptors
Dravid, S. M., Burger, P. B., Prakash, A., Geballe, M. T., Yadav, R., Le, P., Vellano, K. M., Snyder, J. P., & Traynelis, S. F. (2010) · Journal of Neuroscience · doi:10.1523/jneurosci.5390-09.2010 · Cited by 108
Marin, M.-F., Camprodon, J. A., Dougherty, D. D., & Milad, M. R. (2014) · Depression and Anxiety · doi:10.1002/da.22252 · Cited by 106
Translating Across Circuits and Genetics Toward Progress in Fear- and Anxiety-Related Disorders
Ressler, K. J. (2020) · American Journal of Psychiatry · doi:10.1176/appi.ajp.2020.20010055 · Cited by 104
Self-citationGuastella, A. J., Lovibond, P. F., Dadds, M. R., Mitchell, P., & Richardson, R. (2007) · Behaviour Research and Therapy · doi:10.1016/j.brat.2006.07.005 · Cited by 106
Need for speed: Evaluating slopes of OCD recovery in behavior therapy enhanced with d-cycloserine
Chasson, G. S., Buhlmann, U., Tolin, D. F., Rao, S. R., Reese, H. E., Rowley, T., Welsh, K. S., & Wilhelm, S. (2010) · Behaviour Research and Therapy · doi:10.1016/j.brat.2010.03.007 · Cited by 106
Rakofsky, J. J., Ressler, K. J., & Dunlop, B. W. (2011) · Molecular Psychiatry · doi:10.1038/mp.2011.121 · Cited by 112
Self-citationEmpirically Supported Treatments for Panic Disorder
McHugh, R. K., Smits, J. A. J., & Otto, M. W. (2009) · Psychiatric Clinics of North America · doi:10.1016/j.psc.2009.05.005 · Cited by 106
Briscione, M. A., Jovanovic, T., & Norrholm, S. D. (2014) · Frontiers in Psychiatry · doi:10.3389/fpsyt.2014.00088 · Cited by 105
Evidence‐based treatments for PTSD, new directions, and special challenges
Cukor, J., Olden, M., Lee, F. L. F., & Difede, J. (2010) · Annals of the New York Academy of Sciences · doi:10.1111/j.1749-6632.2010.05793.x · Cited by 105
Corcoran, K. A., & Quirk, G. J. (2007) · CNS Spectrums · doi:10.1017/s1092852900020915 · Cited by 111
Abramowitz, J. S., Mahaffey, B. L., & Wheaton, M. G. (2008) · Springer eBooks · doi:10.1002/9780470479216.corpsy0617 · Cited by 110
FROM THE NEUROBIOLOGY OF EXTINCTION TO IMPROVED CLINICAL TREATMENTS
Morrison, F. G., & Ressler, K. J. (2013) · Depression and Anxiety · doi:10.1002/da.22214 · Cited by 107
Self-citationEmpirical support for an involvement of the mesostriatal dopamine system in human fear extinction
Raczka, K. A., Mechias, M.-L., Gartmann, N., Reif, A., Deckert, J., Pessiglione, M., & Kalisch, R. (2011) · Translational Psychiatry · doi:10.1038/tp.2011.10 · Cited by 102
Benedek, D. M., Friedman, M. J., Zatzick, D., & Ursano, R. J. (2009) · FOCUS The Journal of Lifelong Learning in Psychiatry · doi:10.1176/foc.7.2.foc204 · Cited by 103
The NMDA Agonist D-Cycloserine Facilitates Fear Memory Consolidation in Humans
Kalisch, R., Holt, B., Petrović, P., Martino, B. D., Klöppel, S., Büchel, C., & Dolan, R. J. (2008) · Cerebral Cortex · doi:10.1093/cercor/bhn076 · Cited by 102
Schmertz, S. K., & Gerardi, M. A. (2013) · Wiley eBooks · doi:10.1002/9781118528563.wbcbt43 · Cited by 102
Burghardt, N. S., & Bauer, E. P. (2013) · Neuroscience · doi:10.1016/j.neuroscience.2013.05.050 · Cited by 109
Mühlberger, A., Bülthoff, H., Wiedemann, G., & Pauli, P. (2007) · Psychological Assessment · doi:10.1037/1040-3590.19.3.340 · Cited by 101
Torregrossa, M. M., Sanchez, H., & Taylor, J. R. (2010) · Journal of Neuroscience · doi:10.1523/jneurosci.2523-10.2010 · Cited by 100
New Directions in the Cognitive-Behavioral Treatment of OCD: Theory, Research, and Practice
Abramowitz, J. S., Blakey, S. M., Reuman, L., & Buchholz, J. L. (2018) · Behavior Therapy · doi:10.1016/j.beth.2017.09.002 · Cited by 98
Emotional Modulation of Learning and Memory: Pharmacological Implications
LaLumiere, R. T., McGaugh, J. L., & McIntyre, C. K. (2017) · Pharmacological Reviews · doi:10.1124/pr.116.013474 · Cited by 103
GLUCOCORTICOIDS ENHANCE IN VIVO EXPOSURE-BASED THERAPY OF SPIDER PHOBIA
Soravia, L. M., Heinrichs, M., Winzeler, L., Fisler, M. S., Schmitt, W. J., Horn, H., Dierks, T., Strik, W. K., Hofmann, S. G., & de Quervain, D. J. ‐. (2013) · Depression and Anxiety · doi:10.1002/da.22219 · Cited by 98
Neuroenhancement: status quo and perspectives
Normann, C., & Berger, T. (2008) · European Archives of Psychiatry and Clinical Neuroscience · doi:10.1007/s00406-008-5022-2 · Cited by 99
Wolosker, H., & Balu, D. T. (2020) · Translational Psychiatry · doi:10.1038/s41398-020-00870-x · Cited by 106
Onur, O. A., Schlaepfer, T. E., Kukolja, J., Bauer, A., Jeung, H., Patin, A., Otte, D.-M., Shah, N. J., Maier, W., Kendrick, K. M., et al. (2010) · Biological Psychiatry · doi:10.1016/j.biopsych.2010.01.022 · Cited by 97
Norrholm, S. D., Jovanović, T., Gerardi, M. A., Breazeale, K. G., Price, M., Davis, M., Duncan, E., Ressler, K. J., Bradley, B., Rizzo, A., et al. (2016) · Behaviour Research and Therapy · doi:10.1016/j.brat.2016.05.002 · Cited by 96
Self-citationPaolone, G., Botreau, F., & Stewart, J. (2008) · Psychopharmacology · doi:10.1007/s00213-008-1280-y · Cited by 96
Stavropoulos, K. K. M., & Carver, L. J. (2013) · Journal of Child Psychology and Psychiatry · doi:10.1111/jcpp.12061 · Cited by 104
Medial prefrontal cortex stimulation accelerates therapy response of exposure therapy in acrophobia
Herrmann, M. J., Katzorke, A., Busch, Y., Gromer, D., Polak, T. T., Pauli, P., & Deckert, J. (2016) · Brain stimulation · doi:10.1016/j.brs.2016.11.007 · Cited by 95
D-cycloserine Deters Reacquisition of Cocaine Self-Administration by Augmenting Extinction Learning
Dhonnchadha, B. Á. N., Szalay, J. J., Achat‐Mendes, C., Platt, D. M., Otto, M. W., Spealman, R. D., & Kantak, K. M. (2009) · Neuropsychopharmacology · doi:10.1038/npp.2009.139 · Cited by 93
Augmentation of Extinction and Inhibitory Learning in Anxiety and Trauma-Related Disorders
Lebois, L. A. M., Seligowski, A. V., Wolff, J. D., Hill, S. B., & Ressler, K. J. (2019) · Annual Review of Clinical Psychology · doi:10.1146/annurev-clinpsy-050718-095634 · Cited by 97
Self-citationYang, Y.-L., & Lu, K. (2005) · Neuroscience · doi:10.1016/j.neuroscience.2005.04.003 · Cited by 93
Disorders of memory and plasticity in psychiatric disease
Pittenger, C. (2013) · Dialogues in Clinical Neuroscience · doi:10.31887/dcns.2013.15.4/cpittenger · Cited by 92
Farrell, L. J., Waters, A. M., Boschen, M. J., Hattingh, L., McConnell, H. W., Oar, E. L., Collings, N., Zimmer‐Gembeck, M. J., Shelton, D., Ollendick, T. H., et al. (2013) · Depression and Anxiety · doi:10.1002/da.22132 · Cited by 98
Ori, R., Amos, T., Bergman, H., Soares‐Weiser, K., Ipser, J., & Stein, D. J. (2015) · Cochrane Database of Systematic Reviews · doi:10.1002/14651858.cd007803.pub2 · Cited by 104
Perrine, S. A., Eagle, A. L., George, S. A., Mulo, K., Köhler, R., Gerard, J., Harutyunyan, A., Hool, S. M., Susick, L. L., Schneider, B. L., et al. (2016) · Behavioural Brain Research · doi:10.1016/j.bbr.2016.01.056 · Cited by 99
Kaplan, G. B., Heinrichs, S. C., & Carey, R. J. (2010) · Pharmacology Biochemistry and Behavior · doi:10.1016/j.pbb.2010.08.004 · Cited by 92
Mataix‐Cols, D., An, S. K., Lawrence, N., Caseras, X., Speckens, A. E. M., Giampietro, V., Brammer, M. J., & Phillips, M. L. (2008) · European Journal of Neuroscience · doi:10.1111/j.1460-9568.2008.06311.x · Cited by 93
Controlled trial of d-cycloserine adjuvant therapy for treatment-resistant major depressive disorder
Heresco-Levy, U., Javitt, D. C., Gelfin, Y., Gorelik, E., Bar, M., Blanaru, M., & Kremer, I. (2006) · Journal of Affective Disorders · doi:10.1016/j.jad.2006.03.004 · Cited by 89
Siegmund, A., Golfels, F., Finck, C., Halisch, A., Räth, D., Plag, J., & Ströhle, A. (2011) · Journal of Psychiatric Research · doi:10.1016/j.jpsychires.2011.01.020 · Cited by 89
Wells, T. S., Miller, S. C., Adler, A. B., Engel, C. C., Smith, T. C., & Fairbank, J. A. (2011) · International Review of Psychiatry · doi:10.3109/09540261.2011.558833 · Cited by 93
Genetic inactivation of D-amino acid oxidase enhances extinction and reversal learning in micePreprint
Labrie, V., Duffy, S. N., Wang, W., Barger, S. W., Baker, G. B., & Roder, J. (2008) · Learning & Memory · doi:10.1101/lm.1112209 · Cited by 90
Chronic Antidepressant Treatment Impairs the Acquisition of Fear Extinction
Burghardt, N. S., Sigurdsson, T., Gorman, J. M., McEwen, B. S., & LeDoux, J. E. (2012) · Biological Psychiatry · doi:10.1016/j.biopsych.2012.10.012 · Cited by 94
Treating disgust in anxiety disorders.
Mason, E. C., & Richardson, R. (2012) · Clinical Psychology Science and Practice · doi:10.1111/j.1468-2850.2012.01282.x · Cited by 95
Ana, E. J. S., Rounsaville, B. J., Frankforter, T. L., Nich, C., Babuscio, T. A., Poling, J. C., Gonsai, K., Hill, K. P., & Carroll, K. M. (2009) · Drug and Alcohol Dependence · doi:10.1016/j.drugalcdep.2009.04.023 · Cited by 88
Activation Mechanisms of the NMDA Receptor
Blanke, M. L., & VanDongen, A. M. J. (2009) · Europe PMC (PubMed Central) · Cited by 89
Otto, M. W., McHugh, R. K., & Kantak, K. M. (2010) · Clinical Psychology Science and Practice · doi:10.1111/j.1468-2850.2010.01198.x · Cited by 87
Haaker, J., Maren, S., Andreatta, M., Merz, C. J., Richter, J., Richter, S. H., Drexler, S. M., Lange, M. D., Jüngling, K., Nees, F., et al. (2019) · Neuroscience & Biobehavioral Reviews · doi:10.1016/j.neubiorev.2019.09.020 · Cited by 92
The Promise of Extinction Research for the Prevention and Treatment of Anxiety Disorders
Anderson, K. C., & Insel, T. R. (2006) · Biological Psychiatry · doi:10.1016/j.biopsych.2006.06.022 · Cited by 89
Yohimbine Enhancement of Exposure Therapy for Social Anxiety Disorder: A Randomized Controlled Trial
Smits, J. A. J., Rosenfield, D., Davis, M. L., Julian, K., Handelsman, P. R., Otto, M. W., Tuerk, P., Shiekh, M., Rosenfield, B., Hofmann, S. G., et al. (2014) · Biological Psychiatry · doi:10.1016/j.biopsych.2013.10.008 · Cited by 86
Self-citationFear Processing, Psychophysiology, and PTSD
Norrholm, S. D., & Jovanović, T. (2018) · Harvard Review of Psychiatry · doi:10.1097/hrp.0000000000000189 · Cited by 92
Law, C., & Boisseau, C. L. (2019) · Psychology Research and Behavior Management · doi:10.2147/prbm.s211117 · Cited by 101
Effects of D-cycloserine on extinction of learned fear to an olfactory cue
Weber, M., Hart, J., & Richardson, R. (2007) · Neurobiology of Learning and Memory · doi:10.1016/j.nlm.2006.12.010 · Cited by 83
Grillon, C. (2009) · Biological Psychiatry · doi:10.1016/j.biopsych.2009.04.017 · Cited by 80
Novel Approach to the Role of NMDA Receptors in Traumatic Brain Injury
Shohami, E., & Biegon, A. R. (2014) · CNS & Neurological Disorders - Drug Targets · doi:10.2174/18715273113126660196 · Cited by 80
Chhatwal, J. P., Gutman, A. R., Maguschak, K. A., Bowser, M. E., Yang, Y., Davis, M., & Ressler, K. J. (2008) · Neuropsychopharmacology · doi:10.1038/npp.2008.97 · Cited by 80
Self-citationFear extinction in rodents: basic insight to clinical promise
Barad, M. (2005) · Current Opinion in Neurobiology · doi:10.1016/j.conb.2005.10.005 · Cited by 82
Towards new approaches to disorders of fear and anxiety
Dias, B. G., Banerjee, S. B., Goodman, J. V., & Ressler, K. J. (2013) · Current Opinion in Neurobiology · doi:10.1016/j.conb.2013.01.013 · Cited by 79
Self-citationStress and Amygdala Suppression of Metaplasticity in the Medial Prefrontal Cortex
Richter‐Levin, G., & Maroun, M. (2010) · Cerebral Cortex · doi:10.1093/cercor/bhp311 · Cited by 79
Learning and memory in conditioned fear extinction: Effects of d-cycloserine
Vervliet, B. (2007) · Acta Psychologica · doi:10.1016/j.actpsy.2007.07.001 · Cited by 78
Critical brain circuits at the intersection between stress and learning
Bangasser, D. A., & Shors, T. J. (2010) · Neuroscience & Biobehavioral Reviews · doi:10.1016/j.neubiorev.2010.02.002 · Cited by 83
Genomewide DNA methylation analysis in combat veterans reveals a novel locus for PTSD
Mehta, D., Bruenig, D., Carrillo‐Roa, T., Lawford, B., Harvey, W., Morris, C. P., Smith, A. K., Binder, E. B., Young, R. M., & Voisey, J. (2017) · Acta Psychiatrica Scandinavica · doi:10.1111/acps.12778 · Cited by 78
Novel treatment approaches for refractory anxiety disorders
Pollack, M. H., Otto, M. W., Roy-Byrne, P. P., Coplan, J. D., Rothbaum, B. O., Simon, N. M., & Gorman, J. M. (2008) · Depression and Anxiety · doi:10.1002/da.20329 · Cited by 77
Self-citationModulation of fear extinction processes using transcranial electrical stimulation
Abend, R., Jalon, I., Gurevitch, G., Sar-El, R., Shechner, T., Pine, D. S., Hendler, T., & Bar‐Haim, Y. (2016) · Translational Psychiatry · doi:10.1038/tp.2016.197 · Cited by 80
Forcadell, E., Torrents‐Rodas, D., Vervliet, B., Leiva, D., Tortella‐Feliu, M., & Fullana, M. A. (2017) · International Journal of Psychophysiology · doi:10.1016/j.ijpsycho.2017.09.001 · Cited by 88
Krystal, J. H., Tolin, D. F., Sanacora, G., Castner, S. A., Williams, G. V., Aikins, D. E., Hoffman, R. E., & D'Souza, D. C. (2009) · Drug Discovery Today · doi:10.1016/j.drudis.2009.05.002 · Cited by 76
d-Cycloserine Augmentation of Cognitive Behavioral Therapy for Anxiety Disorders: an Update
Hofmann, S. G., Otto, M. W., Pollack, M. H., & Smits, J. A. J. (2014) · Current Psychiatry Reports · doi:10.1007/s11920-014-0532-2 · Cited by 76
Panksepp, J., Fuchs, T. A. E., & Iacobucci, P. (2010) · Applied Animal Behaviour Science · doi:10.1016/j.applanim.2010.09.014 · Cited by 75
Whittle, N., Schmuckermair, C., Gunduz‐Cinar, O., Hauschild, M., Ferraguti, F., Holmes, A., & Singewald, N. (2012) · Neuropharmacology · doi:10.1016/j.neuropharm.2012.06.001 · Cited by 76
Reinecke, A., Thilo, K., Filippini, N., Croft, A., & Harmer, C. J. (2014) · Behaviour Research and Therapy · doi:10.1016/j.brat.2014.07.017 · Cited by 75
Steroidal/neuropeptide interactions in hypothalamus and amygdala related to social anxiety
CHOLERIS, E., DEVIDZE, N., KAVALIERS, M., & PFAFF, D. (2008) · Progress in Brain Research · doi:10.1016/s0079-6123(08)00424-x · Cited by 75
Augmentation of exposure therapy with post-session administration of D-cycloserine
Tart, C. D., Handelsman, P. R., DeBoer, L. B., Rosenfield, D., Pollack, M. H., Hofmann, S. G., Powers, M. B., Otto, M. W., & Smits, J. A. J. (2013) · Journal of Psychiatric Research · doi:10.1016/j.jpsychires.2012.09.024 · Cited by 75
Anxiety-control strategies: Is there room for neutralization in successful exposure treatment?
Parrish, C. L., Radomsky, A. S., & Dugas, M. J. (2008) · Clinical Psychology Review · doi:10.1016/j.cpr.2008.07.007 · Cited by 73
Beyond the dopamine receptor: novel therapeutic targets for treating schizophrenia
Coyle, J. T., Balu, D. T., Benneyworth, M. A., Basu, A. C., & Roseman, A. S. (2010) · Dialogues in Clinical Neuroscience · doi:10.31887/dcns.2010.12.3/jcoyle · Cited by 75
Telch, M. J., Bruchey, A. K., Rosenfield, D., Cobb, A. R., Smits, J. A. J., Pahl, S. A., & Gonzalez-Lima, F. (2014) · American Journal of Psychiatry · doi:10.1176/appi.ajp.2014.13101407 · Cited by 77
Metadata
- Authors
- Ressler, K. J., Rothbaum, B. O., Tannenbaum, L., Anderson, P., Graap, K., Zimand, E., Hodges, L., & Davis, M.
- Affiliations
- Emory University (US)
- Virtually Better (US)
- University of North Carolina at Charlotte (US)
- Venue
- Archives of General Psychiatry
- Publisher
- American Medical Association (AMA)
- Published
- 2004-11-01
- Volume
- 61
- Issue
- 11
- Pages
- 1136
- ISSN
- 0003-990X (ISSN-L)
- OpenAlex
- W2156900283
- Cited by
- 1,063
- References
- 45
- Citations by year
- 2026: 4 · 2025: 13 · 2024: 14 · 2023: 17 · 2022: 54 · 2021: 20 · 2020: 20 · 2019: 31 · 2018: 35 · 2017: 53 · 2016: 30 · 2015: 52 · 2014: 62 · 2013: 74 · 2012: 79
- FWCI
- 82.58
- Type
- journal article
- Language
- en
- Open access
- closed
- Locations
- Archives of General Psychiatry (publishedVersion)
- PubMed (publishedVersion)
- Funders
- National Institute of Mental Health (MH-047840, MH069884, K01MH069884)
- Topics
- Social Sciences › Psychology › Experimental and Cognitive Psychology › Anxiety, Depression, Psychometrics, Treatment, Cognitive Processes
- Life Sciences › Neuroscience › Cognitive Neuroscience › Memory and Neural Mechanisms
- Social Sciences › Psychology › Clinical Psychology › Posttraumatic Stress Disorder Research
- Keywords
- D-cycloserine, acrophobia, specific phobia, NMDA receptor partial agonist, fear extinction, virtual reality exposure therapy, nootropic drugs, adjunctive pharmacotherapy, skin conductance, anxiety disorders, fear learning, avoidance behavior, medication adherence
- MeSH terms
- Adult, Combined Modality Therapy, Cycloserine, Desensitization, Psychologic, Double-Blind Method, Extinction, Psychological, Fear, Female, Humans, Male, Middle Aged, Phobic Disorders, Pilot Projects, Placebos, Psychiatric Status Rating Scales, Receptors, N-Methyl-D-Aspartate, Treatment Outcome
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
